Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ngm Biopharmaceuticals Inc (NGM)

Ngm Biopharmaceuticals Inc (NGM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,407,132
  • Shares Outstanding, K 68,142
  • Annual Sales, $ 103,540 K
  • Annual Income, $ -42,800 K
  • 60-Month Beta N/A
  • Price/Sales 13.31
  • Price/Cash Flow N/A
  • Price/Book 4.29

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.36
  • Number of Estimates 3
  • High Estimate -0.32
  • Low Estimate -0.39
  • Prior Year -0.13
  • Growth Rate Est. (year over year) -176.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.20 +25.25%
on 05/04/20
23.39 -13.25%
on 05/12/20
+2.03 (+11.12%)
since 04/27/20
3-Month
9.24 +119.47%
on 03/18/20
23.39 -13.25%
on 05/12/20
+2.61 (+14.76%)
since 02/27/20
52-Week
8.81 +130.31%
on 10/07/19
23.39 -13.25%
on 05/12/20
+5.34 (+35.72%)
since 05/24/19

Most Recent Stories

More News
NGM Biopharmaceuticals (NGM) Reports Q1 Loss, Tops Revenue Estimates

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 3.45% and 22.33%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

NGM : 20.29 (-1.74%)
NGM Biopharmaceuticals: 1Q Earnings Snapshot

SOUTH SAN FRANCISCO, Calif. (AP) _ NGM Biopharmaceuticals Inc. (NGM) on Wednesday reported a loss of $19.1 million in its first quarter.

NGM : 20.29 (-1.74%)
NGM Biopharmaceuticals: 4Q Earnings Snapshot

SOUTH SAN FRANCISCO, Calif. (AP) _ NGM Biopharmaceuticals Inc. (NGM) on Tuesday reported a loss of $15.9 million in its fourth quarter.

NGM : 20.29 (-1.74%)
Why Earnings Season Could Be Great for NGM Biopharmaceuticals (NGM)

NGM Biopharmaceuticals (NGM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

NGM : 20.29 (-1.74%)
Plug Power (PLUG) to Report Q4 Earnings: What to Expect?

Plug Power's (PLUG) Q4 results are expected to reflect gains from healthy demand in material handling, on-road and stationary markets. High costs and international exposure might have been dragging.

FTR : 0.2600 (+11.02%)
PLUG : 4.33 (+2.61%)
SNDX : 16.85 (+7.39%)
NGM : 20.29 (-1.74%)
The Zacks Analyst Blog Highlights: Moderna, Incyte, Heron Therapeutics and NGM Biopharmaceuticals

The Zacks Analyst Blog Highlights: Moderna, Incyte, Heron Therapeutics and NGM Biopharmaceuticals

INCY : 98.22 (-0.47%)
MRNA : 52.18 (-9.58%)
NGM : 20.29 (-1.74%)
Biotech Stock Roundup: MRNA Surges, Pipeline Updates from INCY, HRTX & NGM Bio

The biotech sector was in focus with pipeline updates from a few small biotech companies.

INCY : 98.22 (-0.47%)
MRNA : 52.18 (-9.58%)
HRTX : 19.00 (+3.04%)
NGM : 20.29 (-1.74%)
Carter's, Exxon Mobil fall; Newmont, Gilead rise

NEW YORK (AP) — Stocks that moved heavily or traded substantially on Monday:

GILD : 74.90 (+2.35%)
CRI : 88.87 (+3.67%)
NGM : 20.29 (-1.74%)
XOM : 46.24 (+0.72%)
NCLH : 17.59 (+9.73%)
UTHR : 116.81 (-1.38%)
NEM : 58.73 (-0.81%)
Horizon Discovery Grants a Multi-Product Use License of its GS knockout CHO K1 Cell Line to NGM Bio

Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Company" or "the Group"), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced that...

HZNQF : 1.2500 (+1.77%)
NGM : 20.29 (-1.74%)
New Medical Device That is Proving Effective Against the Worlds Toughest Viruses, Including: Ebola, Hep C, HIV, West Nile and Smallpox Wins FDA Designation "Breakthrough Device"

USA News Group - A new study published in the journal Molecular Therapy reports that researchers found a drug used in the treatment of HIV that may also suppress Zika virus infection. Zika virus disease...

AEMD : 1.2700 (-3.05%)
NGM : 20.29 (-1.74%)
EBS : 84.13 (+0.14%)
SIGA : 6.14 (+2.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade NGM with:

Business Summary

NGM Biopharmaceuticals Inc. is focused on developing novel therapeutics for underlying cardio-metabolic, liver, oncologic and ophthalmic diseases. The company's product pipeline consists of NGM282, NGM313, NGM120, NGM217, NGM621, NGM386 and NGM395 which are in clinical stage. NGM Biopharmaceuticals Inc....

See More

Key Turning Points

2nd Resistance Point 21.89
1st Resistance Point 21.09
Last Price 20.29
1st Support Level 19.37
2nd Support Level 18.45

See More

52-Week High 23.39
Last Price 20.29
Fibonacci 61.8% 17.82
Fibonacci 50% 16.10
Fibonacci 38.2% 14.38
52-Week Low 8.81

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar